Key facts
- · Holder: James B. Tananbaum · Percent: 6% · SCHEDULE 13G
- · Holder: Perceptive Advisors LLC · Percent: 8.4% · SCHEDULE 13G
- · Holder: Nantahala Capital Management, LLC · Percent: 0% · SCHEDULE 13G/A
- · Holder: Balyasny Asset Management L.P. · Percent: 9.99% · SCHEDULE 13G
- · Holder: Cormorant Asset Management, LP · Percent: 9.99% · SCHEDULE 13G
IRulya Therapeutics Inc. has 13 Schedule 13D or 13G filings on record since 2025-08-14. 8 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Group One Trading LLC | 10.7% | 5,942,906 | SCHEDULE 13G, 2026-03-05 | 2026-02-28 |
| Balyasny Asset Management L.P. | 9.99% | 97,699 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| Cormorant Asset Management, LP | 9.99% | 108,029 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| Ikarian Capital, LLC | 9% | 91,789 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| Perceptive Advisors LLC | 8.4% | 912,853 | SCHEDULE 13G, 2026-10-14 | 2026-10-06 |
| Integrated Core Strategies (US) LLC | 7.2% | 1,403,580 | SCHEDULE 13G, 2026-06-10 | 2026-06-04 |
| James B. Tananbaum | 6% | 652,039 | SCHEDULE 13G, 2026-10-14 | 2026-10-06 |
| Squadron Master Fund LP | 5.6% | 55,173 | SCHEDULE 13G, 2026-08-04 | 2026-07-28 |
| Nantahala Capital Management, LLC | 0% | 0 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Genextra S.p.A. | 0% | 0 | SCHEDULE 13G/A, 2025-10-30 | 2025-07-07 |
Holding shares or following this stake? See who's behind IRulya Therapeutics Inc. and the warning signs.
Free to see. No signup.
Want the whole picture on IRulya Therapeutics Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on IRulya Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on IRulya Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Nantahala Capital Management, LLC | 9.99% | SCHEDULE 13G |
| 2025-10-30 | Genextra S.p.A. | 0% | SCHEDULE 13G/A |
| 2025-11-14 | Nantahala Capital Management, LLC | 9.99% | SCHEDULE 13G/A |
| 2026-03-05 | Group One Trading LLC | 10.7% | SCHEDULE 13G |
| 2026-05-15 | Nantahala Capital Management, LLC | 7.52% | SCHEDULE 13G/A |
| 2026-06-10 | Integrated Core Strategies (US) LLC | 7.2% | SCHEDULE 13G |
| 2026-08-04 | Squadron Master Fund LP | 5.6% | SCHEDULE 13G |
| 2026-08-14 | Nantahala Capital Management, LLC | 0% | SCHEDULE 13G/A |
| 2026-08-14 | Balyasny Asset Management L.P. | 9.99% | SCHEDULE 13G |
| 2026-08-14 | Cormorant Asset Management, LP | 9.99% | SCHEDULE 13G |
| 2026-08-14 | Ikarian Capital, LLC | 9% | SCHEDULE 13G |
| 2026-10-14 | James B. Tananbaum | 6% | SCHEDULE 13G |
| 2026-10-14 | Perceptive Advisors LLC | 8.4% | SCHEDULE 13G |
IRulya Therapeutics Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for IRulya Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.